Inozyme Pharma

General Information
Business:

 

We are a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. Through our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. We are initially focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies.

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 24
Founded: 2015
Contact Information
Address 321 Summer Street, Suite 400, Boston, MA 02210, USA
Phone Number (857) 330-4340
Web Address http://www.inozyme.com
View Prospectus: Inozyme Pharma
Financial Information
Market Cap $349mil
Revenues $0 mil (last 12 months)
Net Income $-22.5 mil (last 12 months)
IPO Profile
Symbol INZY
Exchange NASDAQ
Shares (millions): 7.0
Price range $16.00 - $16.00
Est. $ Volume $112.0 mil
Manager / Joint Managers BofA Securities/ Cowen/ Piper Sandler
CO-Managers Wedbush PacGrow
Expected To Trade: 7/24/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change